BARNSTABLE, Mass., March 27, 2013 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCQB: UVFT) (the "Company") announced today that the Company has retained Stardust Broadcasting to run approximately 500 sixty-second television spots on a variety of national stations, with the intent of building the brand, and educating the consumer about the dangers of indoor air pollution.
"These commercials are the beginning of a long-term program to drive sales, while informing viewers how they can protect their loved ones from the spread of airborne diseases, allergens, and virtually all other forms of indoor air pollution. According to Stardust, the ads will start running later this week on stations such as CNN, ESPN, Fox News, Fox Sports and the Discovery Channel," said Jack Lennon, President of UV Flu.
"We are very excited about this first phase of our ramp-up. We have spent the last 18 months testing and evaluating the many applications for our products, and now we can focus on ramping up production to meet the demand we foresee from addressing the needs of each of these markets," said Mr. Lennon
"It turns out that there are major subsets to the overall residential market that are huge, but need user specific marketing approaches that we are now rolling out. If you have allergies or asthma, are pregnant or have small children, are undergoing any medical treatments, own a pet bird, dog, or cat, are a smoker or the spouse of a smoker, if your home suffers from mold and mildew, if you snore or have sleep problems, or are the spouse of one, or if you work in the field of medicine, education, travel or retail, your health, and the health of your family could be at risk," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the ViraTech UV-400.
About UV Flu Technologies, Inc. (OTCQB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Toll-Free: 1-877-358-5545 (FLU-KILL)
Retail or Internet Inquires:
Please call our Corporate Office at: 508-362-5455
SOURCE UV Flu Technologies, Inc.